Gastritis and gastrointestinal disorders
| 1) Core items |
| Test code |
Test name |
Clinical description |
| S731 |
H. pylori IgG |
Used to identify past infection history; not suitable for confirmation of eradication |
| S474 |
H. pylori IgM |
Can be used as an early infection marker; limited when used alone |
| G302 |
Helicobacter pylori [Real-time PCR] |
Molecular diagnostic test based on endoscopic biopsy specimens, used for confirmation of infection |
| S697 |
Helicobacter pylori Ag |
Useful for screening diagnosis and post-eradication treatment assessment |
| 2) Optional items |
| Test code |
Test name |
Clinical description |
| L420 |
Gastrin [CIA] |
Evaluation of gastric acid secretion function and gastric neuroendocrine tumors |
| W314 |
GastroPanel |
Used to predict atrophic gastritis and identify high-risk groups for gastric cancer |
| E502 |
Pepsinogen Ⅱ |
Assessment of atrophic gastritis and gastric cancer risk |
| E501 |
Pepsinogen I |
Assessment of atrophic gastritis and gastric cancer risk |
| E504 |
Pepsinogen ratio |
Used to complement sensitivity and assess progression of atrophic gastritis |
| 3) Supplementary items |
| Test code |
Test name |
Clinical description |
| N225 |
Clarithromycin resistance test |
Test for detection of clarithromycin resistance used in eradication therapy |
| E404 |
Urea breath test (UBT) |
Diagnostic method for confirming infection status before and after eradication therapy |
| 4) Diagnostic workflow |
| Category |
Step 1 – Initial screening test |
Step 2 – Infection confirmation & Pathological evaluation |
Step 3 – Post-eradication treatment assessment |
| Primary |
H.Pylori Ag, H. pylori IgG, IgM |
H. pylori PCR |
H. pylori Ag |
| Optional |
Gastro Panel, Pepsinogen I/II,
ratio, Gastrin
|
Giemsa stain |
Gastro Panel, Pepsinogen I/II, ratio, Gastrin |
| Adjunctive |
– |
Urea breath test, Clarithromycin resistance mutation test |
Urea breath test |
